Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Diet and stroke

This article was originally published in The Tan Sheet

Executive Summary

There is "strong support for the recommendations to consume more than five servings of fruit and vegetables per day, which is likely to cause a major reduction in strokes," a study published in The Lancet Jan. 28 finds. Feng He, St. George's University of London, et al., reviewed eight studies that were identified through database searches and included 257,551 individuals. There were 4,917 stroke events during the average follow-up period of 13 years. "Compared with individuals who had less than three servings of fruit and vegetables per day, the pooled relative risk of stroke was 0.89 for those with three to five servings per day and 0.74 for those with more than five servings per day." If current recommendations for five or more servings per day were achieved, "stroke morbidity and mortality would be greatly reduced," He et al. conclude...

You may also be interested in...



Teva And Hikma Plan Long-Term Environmental Commitments

Teva has disclosed plans to focus on climate action and resilience, responsible use of natural resources and emissions, effluents and waste, as part of a long-term environmental sustainability commitment. Meanwhile, Hikma has at the same time committed “to further reducing our climate impact and improving the resilience of our business in the face of future climate change.”

Kite Strikes CAR-T Access & Discount Deal For Tecartus In England

Health technology assessment body NICE wants Kite to collect more evidence to prove that Tecartus can cure relapsed or refractory mantle cell lymphoma. But in the meantime, it says the CAR-T therapy should be made available on the National Health Service, making UK patients among the first in the world to be offered access to the treatment.

Germany First As Pfenex And Alvogen Biosimilar Forsteo Is Launched

After launching in the US last year, the teriparatide product developed by Pfenex and Alvogen has been introduced in Europa, via commercialization partner Theramex, beginning with Germany.

Topics

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel